Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer …

Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50
million people were living with chronic hepatitis C based on the World Health Organization …

Background Chronic hepatitis C virus (HCV) infection is more prevalent among patients who
have chronic kidney disease than among those who do not have the disease. Patients with …

Background The revolution in hepatitis C virus (HCV) treatment through the development of
direct-acting antivirals (DAAs) has generated international interest in the global elimination …

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high
response rates (> 95%) and simplified the management of HCV treatment, permitting non …

Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can
be cured in almost all infected patients. This has led to a number of clinical questions …

Background & Aims Chronic hepatitis C virus (HCV) infection is a global health burden.
Although HCV infection rarely contributes to morbidity during childhood, most HCV-infected …

Hepatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality
worldwide and is a leading cause of death in individuals with chronic hepatitis B virus (HBV) …

Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in
Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy …

BACKGROUND There is little evidence about the association of pre-existing hepatitis C
infection (HCV) with outcomes in patients with coronavirus disease 2019 (COVID-19). AIM …